Results 31 to 40 of about 626,377 (227)
PCSK9 inhibitor effectively alleviated cognitive dysfunction in a type 2 diabetes mellitus rat model [PDF]
PeerJBackground The incidence of diabetes-associated cognitive dysfunction (DACD) is increasing; however, few clinical intervention measures are available for the prevention and treatment of this disease.
Yang Yang +4 more
doaj +2 more sources
Are PCSK9 Inhibitors Cost Effective? [PDF]
, 2018 The objective of this study was to review available health economic evaluations of PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors.
Kristiansen, Ivar Sønbø +7 more
core +1 more source
PCSK9 - new perspectives for lipid-lowering pharmacotherapy in patients with coronary artery disease [PDF]
Farmacja Polska, 2020 Optimal hypolipemic therapy reduces the risk of cardiovascular death. The drugs used in Poland are: statins, ion exchange resins, cholesterol absorption inhibitors, fibrates and proprotein subtylsin/cexin type 9 converting enzyme inhibitors (PCSK9).
Natalia Pauli, Monika Rac
doaj +1 more source
Frontiers in Pharmacology, 2022 Background: The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are potent LDL-C lowering agents. However, few head-to-head studies evaluated the efficacy on the lowering in other atherogenic apolipoproteins and safety of PCSK9 ...
Yi-Ting Huang +9 more
doaj +1 more source
A study in high-risk, maximally pretreated patients to determine the potential use of PCSK9 inhibitors at various thresholds of total and LDL cholesterol levels [PDF]
, 2016 PURPOSE OF THE STUDY: Statins and ezetimibe reduce low-density lipoprotein cholesterol (LDL-c) and cardiovascular disease (CVD) risk. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors lower LDL-c by 50%-70% and might be useful in ...
core +1 more source
PCSK9 inhibitors and diabetes mellitus [PDF]
Vnitřní lékařství, 2018 Proproteinconvertase subtilisin kexin 9 (PCSK9) is a key regulator of low-density lipoprotein receptor (LDLR) expression. Anti-PCSK9 monoclonal antibody (MAb) therapy reduces LDL-cholesterol (LDL-C) by ~60 % and reduces also the risk of major adverse cardiovascular events.
Branislav, Vohnout +2 more
openaire +2 more sources
Safety, adherence and efficacy of PCSK9 inhibitors: a retrospective real-world study
Proceedings of Singapore Healthcare, 2022 Introduction PCSK9 inhibitors demonstrated their effectiveness in reducing low-density lipoprotein cholesterol (LDL-C) and cardiovascular events in landmark trials. It remains unclear whether the results can be translated to Asian populations. This study
Bee Ling Kelly Chng +6 more
doaj +1 more source
, 2023 Despite reports on the efficacy of proprotein convertase subtilisin-Kexin type 9 (PCSK9) inhibitors as a potent lipid-lowering agent in various large-scale clinical trials, the anti-atherogenic properties of PCSK9 inhibitors in reducing PCSK9 and ...
Rahayu Zulkapli +3 more
core +1 more source
PCSK9 Inhibition could be Effective for Acute Myocardial Infarction.
, 2022 In this review, we explore the role of PCSK9 and the inhibition of PCSK9 in patients after acute myocardial infarction (MI). Despite the implementation of evidencebased therapies to improve outcomes, one-year mortality remains at 12-15%, and there is ...
Gencer, Baris, Mach, François
core +1 more source
, 2021 PURPOSE: PCSK9 might affect central nervous system development, neuronal apoptosis, and differentiation. We investigate the neurocognitive adverse events associated with the use of PCSK9 inhibitors (alirocumab and evolocumab) using pharmacovigilance ...
VEYRAC, Gwenaelle +5 more
core +1 more source